LON:BPCR

BioPharma Credit Share Forecast, Price & News

GBX 0.98
+0.00 (+0.21 %)
(As of 04/16/2021 03:47 PM ET)
Add
Compare
Today's Range
0.97
Now: GBX 0.98
0.98
50-Day Range
0.96
MA: GBX 0.98
0.99
52-Week Range
0.70
Now: GBX 0.98
1.03
Volume361,106 shs
Average Volume1.24 million shs
Market Capitalization£13.42 million
P/E Ratio10.98
Dividend Yield7.20%
BetaN/A
BioPharma Credit PLC, an investment trust, invests in interest-bearing debt assets secured by royalties or other cash flows derived from the royalties and sales of life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.

Industry, Sector and Symbol

Industry Asset Management
Sub-IndustryN/A
CUSIPN/A
CIKN/A
PhoneN/A
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£150.90 million
Cash FlowGBX 20.79 per share
Book ValueGBX 102.20 per share

Profitability

Miscellaneous

Outstanding Shares1,373,872,000
Market Cap£13.42 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Why Matinas BioPharma Stock Crashed Today
February 1, 2021 |  fool.com
Sun BioPharma changes name to Panbela Therapeutics
December 1, 2020 |  seekingalpha.com
News for AzurRx BioPharma Inc
November 25, 2020 |  markets.businessinsider.com
FDA OK's Eiger BioPharma's Hutchinson-Gilford treatment
November 21, 2020 |  seekingalpha.com
Biopharma Cred. Share News (BPCR)
September 10, 2020 |  lse.co.uk
Brokers bullish on Biopharma Credit shares
June 9, 2020 |  uk.finance.yahoo.com
Jupiter Monthly Alternative Income Fund
May 15, 2020 |  www.bloomberg.com
Biopharma Cred. Regulatory News
March 28, 2020 |  www.lse.co.uk
BioPharma Credit PLC
October 3, 2019 |  markets.ft.com
BioPharma Credit PLC - Net Asset Value(s)
September 21, 2019 |  www.lse.co.uk
Replacement: Dividend Declaration
August 7, 2019 |  markets.ft.com
See More Headlines

MarketRank

Overall MarketRank

1.19 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
GBX 0.98
+0.00 (+0.21 %)
(As of 04/16/2021 03:47 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioPharma Credit (LON:BPCR) Frequently Asked Questions

What stocks does MarketBeat like better than BioPharma Credit?

Wall Street analysts have given BioPharma Credit a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioPharma Credit wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has BioPharma Credit's stock price been impacted by COVID-19?

BioPharma Credit's stock was trading at GBX 0.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BPCR stock has decreased by 0.7% and is now trading at GBX 0.98.
View which stocks have been most impacted by COVID-19
.

How often does BioPharma Credit pay dividends? What is the dividend yield for BioPharma Credit?

BioPharma Credit declared a dividend on Thursday, March 11th. Shareholders of record on Thursday, March 18th will be paid a dividend of GBX 0.02 per share on Friday, April 16th. This represents a dividend yield of 2.1%. The ex-dividend date is Thursday, March 18th. The official announcement can be accessed at this link.
View BioPharma Credit's dividend history
.

Is BioPharma Credit a good dividend stock?

BioPharma Credit pays an annual dividend of GBX 0.07 per share and currently has a dividend yield of 7.20%. BPCR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of BioPharma Credit is 78.65%. Payout ratios above 75% are not desirable because they may not be sustainable.
View BioPharma Credit's dividend history.

Who are BioPharma Credit's key executives?

BioPharma Credit's management team includes the following people:
  • Mr. Pedro Gonzalez de Cosio, Investment Mang.
  • Mr. Pablo G. Legorreta, Investment Mang.
  • Mr. Martin G. Friedman, Investment Mang. (Age 54)

Who are some of BioPharma Credit's key competitors?

What other stocks do shareholders of BioPharma Credit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioPharma Credit investors own include (AFPO.L) (AFPO), Altius Minerals (ATUSF), LiDCO Group Plc (LID.L) (LID), 21512 (SAT.L) (SAT), San Juan Basin Royalty Trust (SJT), ANGLE (AGL), Hochschild Mining (HOC), SPX FLOW (FLOW), Fulcrum Utility Services (FCRM) and DX (Group) (DX).

What is BioPharma Credit's stock symbol?

BioPharma Credit trades on the London Stock Exchange (LON) under the ticker symbol "BPCR."

How do I buy shares of BioPharma Credit?

Shares of BPCR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is BioPharma Credit's stock price today?

One share of BPCR stock can currently be purchased for approximately GBX 0.98.

How much money does BioPharma Credit make?

BioPharma Credit has a market capitalization of £13.42 million and generates £150.90 million in revenue each year.

What is BioPharma Credit's official website?

The official website for BioPharma Credit is www.bpcruk.com.

Where are BioPharma Credit's headquarters?

BioPharma Credit is headquartered at Beaufort HSE, 51 New North Road, EXETER, EX4 4EP, United Kingdom.


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.